{
    "info": {
        "nct_id": "NCT06492616",
        "official_title": "Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study",
        "inclusion_criteria": "* Histopathologically or cytologically confirmed ER-positive (≥ 10% by immunohistochemistry [IHC]), HER2-negative [IHC = 0 or 1, or (IHC = 2 and in situ hybridization [ISH]-negative)] on tumor biopsy or final surgical pathology specimen early stage resected invasive breast cancer without evidence of recurrence or distant metastases, per local laboratory, according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines\n* Participants considered at high risk of recurrence at initial staging\n* Participants who have received at least 24 months but not more than 60 months of endocrine therapy (AIs or tamoxifen) with or without a CDK 4 and CKD 6 inhibitor (CDK4/6i)\n* Participants who received prior CDK4/6i or a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor must have already completed or discontinued these treatments.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participants with inflammatory breast cancer\n* History of any prior (ipsilateral and/or contralateral) invasive breast cancer\n* Participant with history of malignancy within 3 years of the date of randomization, except for adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix\n* Participants who have had more than a 6-month continuous interruption of prior SoC adjuvant endocrine therapy or who discontinued adjuvant endocrine therapy more than 6 months prior to randomization\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "* Participants who received prior CDK4/6i or a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor must have already completed or discontinued these treatments.",
            "criterions": [
                {
                    "exact_snippets": "Participants who received prior CDK4/6i ... must have already completed or discontinued these treatments.",
                    "criterion": "prior CDK4/6 inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "completion or discontinuation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who received prior ... poly adenosine diphosphate-ribose polymerase (PARP) inhibitor ... must have already completed or discontinued these treatments.",
                    "criterion": "prior PARP inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "completion or discontinuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants considered at high risk of recurrence at initial staging",
            "criterions": [
                {
                    "exact_snippets": "Participants considered at high risk of recurrence at initial staging",
                    "criterion": "risk of recurrence at initial staging",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received at least 24 months but not more than 60 months of endocrine therapy (AIs or tamoxifen) with or without a CDK 4 and CKD 6 inhibitor (CDK4/6i)",
            "criterions": [
                {
                    "exact_snippets": "received at least 24 months but not more than 60 months of endocrine therapy (AIs or tamoxifen)",
                    "criterion": "duration of endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 24,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "endocrine therapy (AIs or tamoxifen)",
                    "criterion": "type of endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "aromatase inhibitors (AIs)",
                                "tamoxifen"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without a CDK 4 and CKD 6 inhibitor (CDK4/6i)",
                    "criterion": "CDK4/6 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "concomitant therapy",
                            "expected_value": "with or without CDK4/6 inhibitor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histopathologically or cytologically confirmed ER-positive (≥ 10% by immunohistochemistry [IHC]), HER2-negative [IHC = 0 or 1, or (IHC = 2 and in situ hybridization [ISH]-negative)] on tumor biopsy or final surgical pathology specimen early stage resected invasive breast cancer without evidence of recurrence or distant metastases, per local laboratory, according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines",
            "criterions": [
                {
                    "exact_snippets": "Histopathologically or cytologically confirmed",
                    "criterion": "breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histopathology",
                                "cytology"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ER-positive (≥ 10% by immunohistochemistry [IHC])",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "positivity threshold",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "immunohistochemistry (IHC)"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative [IHC = 0 or 1, or (IHC = 2 and in situ hybridization [ISH]-negative)]",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "negativity definition",
                            "expected_value": [
                                "IHC = 0",
                                "IHC = 1",
                                "IHC = 2 and ISH-negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "on tumor biopsy or final surgical pathology specimen",
                    "criterion": "specimen type",
                    "requirements": [
                        {
                            "requirement_type": "specimen source",
                            "expected_value": [
                                "tumor biopsy",
                                "final surgical pathology specimen"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "early stage resected invasive breast cancer",
                    "criterion": "breast cancer stage and type",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "early"
                        },
                        {
                            "requirement_type": "resection status",
                            "expected_value": "resected"
                        },
                        {
                            "requirement_type": "invasiveness",
                            "expected_value": "invasive"
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of recurrence or distant metastases",
                    "criterion": "recurrence or metastasis",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "distant metastases",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "per local laboratory, according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines",
                    "criterion": "testing standards",
                    "requirements": [
                        {
                            "requirement_type": "guideline adherence",
                            "expected_value": "ASCO/CAP guidelines"
                        },
                        {
                            "requirement_type": "laboratory",
                            "expected_value": "local"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participants with inflammatory breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Participants with inflammatory breast cancer",
                    "criterion": "inflammatory breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any prior (ipsilateral and/or contralateral) invasive breast cancer",
            "criterions": [
                {
                    "exact_snippets": "History of any prior (ipsilateral and/or contralateral) invasive breast cancer",
                    "criterion": "invasive breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of prior occurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant with history of malignancy within 3 years of the date of randomization, except for adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix",
            "criterions": [
                {
                    "exact_snippets": "history of malignancy within 3 years of the date of randomization",
                    "criterion": "history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix",
                    "criterion": "type of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "adequately treated basal cell skin cancer",
                                "adequately treated squamous cell skin cancer",
                                "superficial bladder cancer",
                                "carcinoma in situ of the cervix"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have had more than a 6-month continuous interruption of prior SoC adjuvant endocrine therapy or who discontinued adjuvant endocrine therapy more than 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "more than a 6-month continuous interruption of prior SoC adjuvant endocrine therapy",
                    "criterion": "interruption of prior SoC adjuvant endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "continuity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "discontinued adjuvant endocrine therapy more than 6 months prior to randomization",
                    "criterion": "discontinuation of adjuvant endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since discontinuation",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}